Guide
21 CFR 111 Readiness: Surviving the Subpart E and Subpart F Inspection
21 CFR Part 111 is FDA's current Good Manufacturing Practice regulation for dietary supplements. It runs to 11 subparts (A through P) covering personnel, physical plant, equipment, production, quality control, packaging, labelling, holding, distribution, returned product, complaints and records. But the FDA-483 enforcement data is unambiguous: Subpart E (production and process controls for testing component identity at 21 CFR 111.75) and Subpart F (production and process control records at 21 CFR 111.103) account for the majority of supplement-plant observations year after year. This guide is a working operator's map of the two hot subparts plus the broader 111 frame V5 keeps inspection-ready.
Start free trial Free trial, no credit card, onboard in days, not months.
Subpart E — component identity testing at 21 CFR 111.75
21 CFR 111.75 requires the manufacturer to conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, before using the component. A supplier COA on its own is not sufficient unless the manufacturer has qualified the supplier under 21 CFR 111.75(a)(2) — a high bar most plants have not met. The practical consequence: in-house identity testing on every incoming lot of every dietary ingredient component, with method validation evidence and analyst training records on file. Botanical identity (FTIR, HPTLC, DNA barcoding) is the most-cited gap because supplier COAs commonly mis-identify species.
Subpart F — master manufacturing record and batch production record
21 CFR 111.205 requires a written master manufacturing record (MMR) for each unique formulation and batch size. 21 CFR 111.255 requires a batch production record (BPR) for each batch, with every specification verified, every deviation investigated, every quality-control review signed. The most-cited Subpart F gaps are missing MMR for a marketed product, BPRs without complete in-process checks, and specification deviations released without documented investigation. These are paperwork failures rather than chemistry failures — which is why a system that generates the records as work happens closes most of the gap.
Subpart G/H/J — finished-product testing, packaging/labelling, returns and reserve
Three further subparts drive most of the remaining citations. Subpart G (21 CFR 111.123) requires finished-product testing or a documented exemption under 21 CFR 111.75(d). Subpart H (21 CFR 111.140–155) requires packaging and labelling controls, including label reconciliation. Subpart J (21 CFR 111.260) requires reserve sample retention for one year past shelf-life. A typical 483 cluster hits two or three of these together — finished-product spec missing, label reconciliation gap, reserve sample under-sized.
Records, signatures and the 21 CFR Part 11 overlay
21 CFR 111 records are subject to 21 CFR Part 11 if they are kept electronically. The practical impact is system validation under Part 11 — closed-system controls, audit trail, electronic signature binding, validated retention. A plant that runs paper batch records sidesteps Part 11 but pays in reconstruction time. A plant that runs electronic records under Part 11 pays in validation evidence but cuts inspection time dramatically. V5 is built for the electronic path with the validation evidence shipped as part of the product.
A 60-day Subpart E + Subpart F readiness path
Days 1–10: component-by-component mapping — every dietary ingredient SKU, its identity-test method, validation evidence currency, analyst training. Days 11–25: receiving-to-release workflow rebuild — incoming lot hold, identity test, supplier-COA cross-check, release authority. Days 26–40: MMR and BPR audit — every marketed SKU has a current MMR, every recent batch has a complete BPR, deviations investigated. Days 41–55: Subpart G/H/J spot audits — finished product, label reconciliation, reserve samples. Days 56–60: mock FDA inspection with paper-and-system reconciliation.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Can we rely on a supplier COA for component identity?
Only if you have qualified the supplier under 21 CFR 111.75(a)(2), which is a defined process FDA expects to be documented and periodically re-verified. In practice almost no plants have a qualified-supplier exemption that survives inspection, so in-house identity testing on each incoming dietary ingredient lot is the operating standard.
What identity-test method does FDA expect for botanicals?
FDA does not mandate a specific method but expects "appropriate" — meaning a method validated to distinguish the species from likely adulterants. FTIR and HPTLC are the working defaults; DNA barcoding is gaining ground for difficult botanicals. Whatever method the plant uses must have validation evidence on file.
How long do 21 CFR 111 records need to be retained?
Records must be kept for one year past shelf-life of the batch or two years past distribution, whichever is later, under 21 CFR 111.605. Reserve samples must be retained at least one year past shelf-life under 21 CFR 111.83. Complaint records under Subpart O follow the same window.
Does 21 CFR 111 apply to brand-owners who don't manufacture?
Yes — under 21 CFR 111.12 the "own-label distributor" is responsible for 21 CFR 111 compliance of the products it markets. A brand that uses a contract manufacturer must hold the master record, qualify the manufacturer, and treat the manufacturer's batch records as its own for retention and inspection purposes.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- Dietary Supplement cGMP Readiness: The V5 Hub
- NDI Notification Readiness: 21 CFR 190.6 New Dietary Ingredient Dossier
- NSF 173 & USP <2750> Readiness: Third-Party Supplement Certification
- Structure/Function Claims Readiness: DSHEA §6, Disclaimers & Substantiation
- Supplement AER Readiness: DSHEA Title II Serious Adverse Event Reporting
- Supplement Identity Testing Readiness: 21 CFR 111 Subpart E
Spot something off? .